Valneva’s Japanese encephalitis vaccine is licensed in more than thirty-five countries. It is marketed under the trade names IXIARO® in North America, Europe, Hong Kong, Singapore and Israel and under the trade name JESPECT® in Australia and New Zealand where it is distributed by Seqirus.
Valneva manufactures the IXIARO®/JESPECT® vaccine at its fully-owned cGMP facilities in Livingston, Scotland. The site is licensed and operates under a Manufacturing Authorisation granted by the Medicines and Healthcare products Regulatory Agency (“MHRA”) and is also registered by the US FDA.
Since the approval of IXIARO®/JESPECT® in 2009, Valneva has been focusing on increasing penetration through its sales and marketing activities and global expansion strategy.
Valneva’s revenues from IXIARO®/JESPECT®‘s product sales amounted to €69.6 million in 2018.
Select your country to learn more:Valneva AustriaValneva Canada
Valneva NordicValneva UKValneva US